We have assessed the haemodynamic effects of rapacuronium (Org 9487) in adults undergoing cardiac surgery and compared these with vecuronium and placebo. We studied 56 adult patients undergoing coronary artery bypass grafting or valve replacement surgery using a fentanyl-based anaesthetic technique. A pulmonary artery flotation catheter was inserted before induction of anaesthesia. After induction, tracheal intubation and stabilization of haemodynamic measurements, subjects were allocated randomly to receive rapacuronium 1.5 mg kg -1 , vecuronium 0.1 mg kg -1 or saline placebo. Haemodynamic measurements were made before drug administration and 1, 3, 5 and 10, and if possible, 15 min after administration. Rapacuronium was associated with statistically significant increases in heart rate (17%) and cardiac index (15%) and decreases in mean arterial pressure (11%) and systemic vascular resistance (18%), whereas vecuronium and placebo were associated with significant decreases in heart rate only (14-15%) (PϽ0.05). No cutaneous signs of histamine release were observed. Clinically, the results were within acceptable limits. Our results suggest that administration of rapacuronium may be associated with significant changes in heart rate and arterial pressure in patients undergoing coronary artery bypass grafting. 1999; 83: 721-6 Keywords: neuromuscular block, rapacuronium; neuromuscular block, vecuronium; neuromuscular block, Org 9487; cardiovasular system, effects; surgery, cardiovascular Accepted for publication: June 16, 1999 Rapacuronium (Org 9487) is a new aminosteroidal, non-Patients and methods depolarizing neuromuscular blocking agent of low potency We studied 56 adult patients, ASA II-IV, undergoing which has been shown to have a rapid effect in animal 1 elective coronary artery bypass graft (CABG) or valvular and early human studies. 2 3 Human studies showed that a surgery (with or without CABG), after obtaining written dose of 1.5 mg kg -1 had an onset profile similar to that of informed consent and approval from the University Ethics succinylcholine and recovery was rapid if neostigmine was Committee. Patients with a history of uncontrolled cardiac administered.
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arrhythmias, unstable angina or myocardial infarction within Initial haemodynamic studies with rapacuronium have the previous 3 months were excluded. Other exclusion shown conflicting results. Whereas Fleming, Safwat and criteria were significant hepatic, renal or neuromuscular Wurschmidt 4 reported minimal changes similar to those of disorders. Patients with a recently documented left rocuronium, Witkowski and colleagues 5 reported a dose-ventricular ejection fraction (LVEF) ജ45% and/or left related increase in heart rate after administration of ventricular end-diastolic pressure (LVEDP) Ͻ16 mm Hg rapacuronium, with a dose of 1.5 mg kg -1 resulting in an were included. These were determined by cardiac increase in heart rate of approximately 17%. The number catheterization within 6 months of the study or by a of patients in these studies was relatively small. The purpose recent transthoracic echocardiogram to confirm LVEF, in of our study was to investigate the haemodynamic effects of rapacuronium compared with vecuronium and placebo during fentanyl anaesthesia in patients undergoing cardiac †Presented in part at the Anaesthetic Research Society, Belfast
Meeting, March 1998 (Br J Anaesth 1998; 81: 282-3P).
surgery. surgery were receiving calcium entry blocking agents, beta receptor blockers and nitrates, and continued on their medication until the morning of surgery. Seven patients corrected QT interval (QT c ) values were derived from undergoing valve surgery were receiving no regular measured haemodynamic variables using standard formulae. medications; the remainder were receiving digoxin, calcium Statistical analysis of the results within each group was entry blockers, diuretics and angiotensin-converting enzyme made by repeated measures analysis of variance followed inhibitors alone, or in combination.
by Hochberg-Bonferroni tests for pairwise comparisons. Monitoring of heart rate and rhythm, and ST segment Between-group analysis was performed by analysis of analysis was commenced on arrival in the anaesthetic variance followed by the Tukey post-test where appropriate. room. Peripheral venous and radial arterial catheters were PϽ0.05 was taken to represent statistical significance. inserted under local anaesthesia. A multi-lumen thermodilution pulmonary artery flotation catheter (Baxter 831HF75)
Results
was inserted via the right internal jugular vein. Heart rate and QT interval (using a rhythm strip), mean systemic We studied 56 patients (41 CABG, 15 valve surgery with/without CABG). Two patients were excluded after arterial pressure (MAP), mean pulmonary artery pressure (MPAP), central venous pressure (CVP), pulmonary capil-randomization because of elevation of the ST segment of the ECG immediately after intubation but before administralary wedge pressure (PCWP) and cardiac output (CO) were recorded before induction of anaesthesia. CO measurements tion of the study drug in one patient and coincidental hyperkalaemia excluding the use of succinylcholine in were made at end-expiration in triplicate using a thermodilution technique with 10 ml of iced 5% dextrose in water the other.
Patient characteristics were comparable between groups and a cardiac output computer (Hewlett Packard Component Monitoring System, model No. 68S); the mean of three (Table 1) . Because of the need to administer cardioactive drugs before the study drug was given, data from five other readings was used.
Anaesthesia was induced with fentanyl 25-50 µg kg -1 patients were excluded from statistical analysis.
Mean haemodynamic values for all patients before inducand midazolam 2-5 mg i.v., and oxygen was administered by face mask. Succinylcholine 1.0 mg kg -1 was given tion of anaesthesia, at baseline (i.e. immediately before administration of the study drug) and after administration at loss of consciousness to facilitate tracheal intubation. Patients' lungs were ventilated to normocapnia (end-tidal of the study drug are shown in Table 2 . Mean heart rate in the group who received rapacuronium increased from 54 carbon dioxide partial pressure of 4.5-5.0 kPa) using an air-oxygen mixture (FI O 2 0.5). Additional bolus doses of beat min -1 to a maximum of 63 beat min -1 at 3-10 min (PϽ0.05), representing an increase of approximately 17% fentanyl and/or midazolam were administered as indicated. After recovery from succinylcholine, as demonstrated by compared with baseline. Administration of vecuronium was associated with a significant decrease in heart rate an acceleration monitor (TOF-Guard, Biometer Ltd, Odense, Denmark), and stable haemodynamic measure-throughout the study (maximum of 14% at 5-10 min) as was also the case for saline at 3-10 min (maximum of 15% ments, as demonstrated by changes of less than 5% in HR and MAP for 3 min, baseline haemodynamic recordings at 10 min) (both PϽ0.05). The increase in heart rate in the rapacuronium group was statistically significant compared were made as outlined above. Patients were then allocated randomly (generated using a computer) to receive a bolus with the vecuronium group at 1 min and with both the vecuronium and saline groups at 3-10 min (PϽ0.05). dose of rapacuronium 1.5 mg kg -1 (group R), vecuronium 0.1 mg kg -1 (group V) or saline placebo 5 ml (group P), MAP decreased significantly after administration of rapacuronium from 3 min onwards, with a maximum administered over 5 s. Separate randomization schedules were used for patients undergoing CABG and valve surgery. reduction of approximately 11% at 3 and 5 min (PϽ0.05).
There were no significant changes in MAP after administraThe dose of rapacuronium used in the study was used previously for facilitating intubation and providing relaxa-tion of vecuronium or saline. In addition, changes in MAP were not significant between groups. There were small and tion for short procedures, 2 and represents the lower end of the range of clinically useful doses. Haemodynamic clinically unimportant but statistically significant changes in MPAP after vecuronium and saline. Statistically significant measurements were repeated 1, 3, 5 and 10 and, if possible, 15 min after administration of the study drug.
changes also occurred in CVP in all groups and in PCWP after rapacuronium and saline (Table 2 ). All haemodynamic measurements were completed before surgical stimulation. Cardiac index (CI), systemic vascular Cardiac index increased significantly from a mean baseline value of 2.05 litre min -1 m -2 after rapacuronium to a resistance (SVR), pulmonary vascular resistance (PVR) and Table 2 Haemodynamic variables and derived calculations before anaesthesia (Pre-induction), before administration of the study drug (Baseline) and 1, 3, 5, 10 and 15 min after drug administration (mean (SD)). Rapacuronium (nϭ15), vecuronium (nϭ18) and saline (nϭ16), except a 17, b maximum of 2.35 litre min -1 m -2 at 10 min (maximum heart rate and cardiac index (17% and 15%, respectively) and change 15%; PϽ0.05). SVR decreased after administra-decreases in mean arterial pressure and systemic vascular tion of rapacuronium, from a mean baseline value of resistance (11% and 18%, respectively) in patients under-1437 dyn s cm -5 to a minimum of 1177 dyn s cm -5 at going cardiac surgery. While these changes were statistically 3 min (maximum change 18%; PϽ0.05). This significant significant, they were of limited clinical significance at change persisted throughout the study. There were no this dose. significant changes in CI or SVR after vecuronium or saline There is only limited work on the haemodynamic effects and there were no significant changes in PVR in any group of rapacuronium, but preliminary results from initial studies throughout the study. Changes in CI and SVR were not are largely in agreement with our findings. [4] [5] [6] [7] Miguel and significant between groups.
colleagues showed dose-related increases of greater than Tables 3 and 4 show the haemodynamic variables for the 30% in heart rate in 21% and 55% of patients given CABG and valve replacement subgroups. The results in the rapacuronium 1.5 or 2.5 mg kg -1 , respectively, during larger CABG subgroup (Fig. 1 ) mirrored closely the overall propofol-low dose fentanyl-nitrous oxide anaesthesia. 6 results of the study. Changes were significant less frequently Witkowski and colleagues also showed short-lasting doseand often of a smaller magnitude in the smaller subgroup related increases in heart rate of 17% and 30% after of valve surgery patients.
administration of rapacuronium 1.5 and 2.5 mg kg -1 , respecThere were no significant changes in QT c interval after tively, with no significant changes in arterial pressure. 5 The administration of rapacuronium or in the two other groups, extent of the increase in heart rate after rapacuronium and there were no significant changes in ST segment. 1.5 mg kg -1 was similar to that in our study. It is not Erythema or bronchospasm was not observed in any patient. possible to speculate on a dose-related effect from our findings as only a single dose of rapacuronium was used.
Discussion
The mechanisms by which neuromuscular blocking agents produce cardiovascular effects are muscarinic We have shown that administration of rapacuronium 1.5 mg kg -1 was associated with significant increases in receptor block, ganglion block, increased release of Table 3 CABG subgroup (nϭ41). Haemodynamic variables immediately before administration of the study drug (Baseline) and 1, 3, 5, 10 and 15 min after administration of the study drug (mean (SD)). Rapacuronium (nϭ12), vecuronium (nϭ14) and saline (nϭ12), except a 12, b 11, Table 4 Valve replacement subgroup (nϭ15). Haemodynamic variables immediately before administration of the study drug (Baseline) and 1, 3, 5 and 10 min after administration of the study drug (mean (SD)). Rapacuronium (nϭ3), vecuronium (nϭ4) and saline (nϭ4). *PϽ0.05 compared with baseline; ϩPϽ0.05 compared with saline norepinephrine and block of its reuptake, histamine libera-hypotension and a low SVR, are characteristic of histamine release, which may be related to both the dose tion and, possibly, direct vasodilatation. Block of muscarinic M 2 receptors in the heart occurs with a range of amino-and speed with which certain neuromuscular blockers are administered. [10] [11] [12] Histamine release is known to be uncomsteroidal blockers, most notably pancuronium, and may lead to vagal block and a resultant tachycardia. 8 9 In mon with aminosteroid blockers, but it may have contributed to the haemodynamic changes observed in our study. the cat, the vagal:neuromuscular blocking dose ratio of rapacuronium is 3:1. 1 This is similar to that for pancuronium, Increased plasma histamine concentrations in association with a lowered mean arterial pressure have been reported and may contribute to increased heart rate after administration of rapacuronium. However, this would only explain the after rapid administration of higher doses of rapacuronium. 13 In that study, peak concentrations of histamine of approxioccurrence of tachycardia and not the other haemodynamic changes (MAP and SVR) observed in our study. The mately 1 ng ml -1 occurred 1 min after administration of rapacuronium. Histamine liberation has been reported decrease in heart rate in the groups that received vecuronium and placebo probably reflects the influence of high-dose previously with steroid blockers of low potency. 14 15 No patient in our study exhibited cutaneous manifestations fentanyl. It may also be a result of lack of any surgical stimulation in the absence of any significant effects of of histamine release, although erythema, tachycardia and bronchospasm have been reported after administration of vecuronium and saline.
Tachycardia and a high cardiac index, together with rapacuronium. 16 Recent in vitro work has shown that rapacuronium may was associated with increases in heart rate and cardiac index and decreases in mean arterial pressure and systemic have the potential to produce vasodilatation compared with vecuronium. 17 18 This vasodilatation, possibly mediated vascular resistance. These findings are consistent with a direct vasodilating effect or an effect such as that observed via inhibition of voltage-activated calcium channels, may account for some of the haemodynamic changes after with histamine liberation. administration of rapacuronium. Ganglion block is observed with aminosteroid blockers only in very high doses. 19-21
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